Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancer Specialty Channel

Gastrointestinal Cancer
Specialty Channel
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
Conference Coverage
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
Conference Coverage
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
Conference Coverage
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology
News
Lenvatinib Added to Pembrolizumab and Chemotherapy Fails to Improve OS in Metastatic Esophageal Squamous Cell Carcinoma
10/17/2025
Stephanie Holland
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results...
10/17/2025
Oncology
News
Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive Gastric or GEJ Cancer
10/17/2025
Janelle Bradley
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy...
10/17/2025
Oncology
News
Durvalumab Plus FLOT Improves OS in Resectable Gastric and GEJ Adenocarcinoma
10/17/2025
Janelle Bradley
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial...
10/17/2025
Oncology
News
Second-Line Trastuzumab Deruxtecan for Patients With HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
08/01/2025
Stephanie Holland
According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...
According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...
According to results from the...
08/01/2025
Oncology
Conference Coverage
Durvalumab Plus FLOT Improved EFS for Patients With Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
07/03/2025
Allison Casey
According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...
According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...
According to the MATTERHORN...
07/03/2025
Oncology

News

News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
Conference Coverage
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
Conference Coverage
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
Conference Coverage
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology
News
Lenvatinib Added to Pembrolizumab and Chemotherapy Fails to Improve OS in Metastatic Esophageal Squamous Cell Carcinoma
10/17/2025
Stephanie Holland
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results...
10/17/2025
Oncology
News
Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive Gastric or GEJ Cancer
10/17/2025
Janelle Bradley
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy...
10/17/2025
Oncology
News
Durvalumab Plus FLOT Improves OS in Resectable Gastric and GEJ Adenocarcinoma
10/17/2025
Janelle Bradley
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial...
10/17/2025
Oncology
News
Second-Line Trastuzumab Deruxtecan for Patients With HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
08/01/2025
Stephanie Holland
According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...
According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...
According to results from the...
08/01/2025
Oncology

Interactive Features

Quiz
Quiz: Which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
10/17/2022
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy...
10/17/2022
Oncology
Test Your Knowledge
Quiz: Identifying Biliary Tract Cancers
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology
Quiz
Quiz: Does Atorvastatin-Metformin Combo Reduce HCC Progression?
08/09/2021
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology
Test Your Knowledge
Quiz: Is Avapritinib a Treatment Option for Patients with Unresectable PDGFRA D842V-Mutant GIST?
08/21/2020
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology
Test Your Knowledge
Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology
Test Your Knowledge
Quiz: Should Pembrolizumab Be New Standard of Care for MSI-H/dMMR Metastatic CRC?
06/04/2020
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab...
06/04/2020
Oncology

Recent News

News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
Conference Coverage
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
Conference Coverage
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
Conference Coverage
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology
News
Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive Gastric or GEJ Cancer
10/17/2025
Janelle Bradley
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy...
10/17/2025
Oncology
News
Durvalumab Plus FLOT Improves OS in Resectable Gastric and GEJ Adenocarcinoma
10/17/2025
Janelle Bradley
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial...
10/17/2025
Oncology
News
Second-Line Trastuzumab Deruxtecan for Patients With HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
08/01/2025
Stephanie Holland
According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...
According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...
According to results from the...
08/01/2025
Oncology
Conference Coverage
Durvalumab Plus FLOT Improved EFS for Patients With Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
07/03/2025
Allison Casey
According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...
According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...
According to the MATTERHORN...
07/03/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use